ClinicalTrials.gg
Not yet recruitingNCT07946848Updated Nov 18, 2026

Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.

A Phase 2 interventional study of Atebimetinib and Cemiplimab in NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer and Metastatic Non-Small Lung Cell Cancer, sponsored by Immuneering Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Immuneering Corporation · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer

02

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • Non-Squamous Non Small Cell Lung Cancer
  • Metastatic Non-Small Lung Cell Cancer
  • Locally Advanced Non-Small Cell Lung Cancer
  • Lung Cancer (NSCLC)

Keywords

  • Atebimetinib
  • IMM-1-104
  • MEK 1/2 inhibitor
  • Cemiplimab
  • Carboplatin
  • Pemetrexed
  • KRAS
  • NRAS
  • RAS Mutation
  • MAPK Pathway
  • PD-L1
  • First-line
  • NSCLC
  • Lung Cancer
  • HRAS
03

In context

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

This study's planned enrollment of 100 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Immuneering Corporation is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or disease. Prior or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
  • (at least 1 target lesion) per 1.1.
  • performance status of 0 or 1.
  • score determined by an FDA-approved test.
  • RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid is acceptable.
  • Adequate organ function:

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow oral medications.
  • EGFR, ALK or ROS1 mutation.
  • Untreated or unresolved
  • Encephalitis, meningitis or uncontrolled seizures in the year before .
  • History of interstitial lung disease non-infectious pneumonitis that required doses of , or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
  • Active disease that required systemic treatment in the past 12 months.
  • A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
  • Prior allogeneic tissue or solid organ transplant.
  • Never-smoker (fewer than 100 cigarettes in a lifetime).
  • Prior or anti-PD-L1 therapy.
  • Impaired cardiac function or cardiac disease, including \<50% by ECHO or MUGA or screening >470 msec.
  • History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
  • History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
  • Rhabdomyolysis within 3 months before Study Day 1.
  • Major surgery or significant traumatic injury within 4 weeks before the first dose.
  • Another .
  • Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
  • Uncontrolled , or infection; immunodeficiency; or active or latent tuberculosis.
  • within 4 weeks before the first dose.
  • COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
  • Known to any study drug or .
  • Unwillingness to use effective
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Atebimetinib + Cemiplimab ± Chemotherapy

    Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 \<50%. The expansion uses the atebimetinib dose selected during dose optimization.

    Drug: Atebimetinib · Biological: Cemiplimab · Drug: Carboplatin · Drug: Pemetrexed (500 mg/m²)

Interventions

  • DrugAtebimetinib

    Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg

    Also known as: IMM-1-104

  • BiologicalCemiplimab

    Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks

    Also known as: REGN2810, Libtayo

  • DrugCarboplatin

    AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4

  • DrugPemetrexed (500 mg/m²)

    500 mg/m² IV on Day 1 of Cycles 1-4

    Also known as: Alimta

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib

    Measured in dose optimization

    Time frame: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.

  2. Objective Response Rate (ORR)

    Percentage of participants with complete or partial response per RECIST 1.1

    Time frame: Every 8 weeks, up to approximately 24 months

Secondary outcomes

  1. Median Progression-Free Survival (PFS)

    Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first.

    Time frame: Up to approximately 24 months.

  2. Overall Survival (OS)

    Time from Cycle 1 Day 1 to death from any cause.

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.

  3. Number of Participants with adverse events

    Treatment-emergent and treatment-related AEs per CTCAE v6.0

    Time frame: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2029, 29 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 29 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
May 2029
CompletionEst.
Jul 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946848
Lead sponsor
Immuneering Corporation
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

IMM1104-201 Study Team
Contact
clinicaltrials@immuneering.com
(860) 321-1302
Vinny Hayreh
study director · Immuneering Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion